BR0013202A - Produção de vìrus sincicial respiratório recombinante expressando moléculas moduladoras imunes - Google Patents
Produção de vìrus sincicial respiratório recombinante expressando moléculas moduladoras imunesInfo
- Publication number
- BR0013202A BR0013202A BR0013202-0A BR0013202A BR0013202A BR 0013202 A BR0013202 A BR 0013202A BR 0013202 A BR0013202 A BR 0013202A BR 0013202 A BR0013202 A BR 0013202A
- Authority
- BR
- Brazil
- Prior art keywords
- interleukin
- recombinant
- immune modulating
- production
- respiratory syncytial
- Prior art date
Links
- 241000725643 Respiratory syncytial virus Species 0.000 title abstract 4
- 230000002519 immonomodulatory effect Effects 0.000 title abstract 4
- 102000004127 Cytokines Human genes 0.000 abstract 3
- 108090000695 Cytokines Proteins 0.000 abstract 3
- 241000700605 Viruses Species 0.000 abstract 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 abstract 2
- 102000014150 Interferons Human genes 0.000 abstract 2
- 108010050904 Interferons Proteins 0.000 abstract 2
- 102000000588 Interleukin-2 Human genes 0.000 abstract 2
- 108010002350 Interleukin-2 Proteins 0.000 abstract 2
- 102000004388 Interleukin-4 Human genes 0.000 abstract 2
- 108090000978 Interleukin-4 Proteins 0.000 abstract 2
- 102000000743 Interleukin-5 Human genes 0.000 abstract 2
- 108010002616 Interleukin-5 Proteins 0.000 abstract 2
- 102000004889 Interleukin-6 Human genes 0.000 abstract 2
- 108090001005 Interleukin-6 Proteins 0.000 abstract 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 2
- 229940079322 interferon Drugs 0.000 abstract 2
- 229940028885 interleukin-4 Drugs 0.000 abstract 2
- 229940100602 interleukin-5 Drugs 0.000 abstract 2
- 229940100601 interleukin-6 Drugs 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 102000003390 tumor necrosis factor Human genes 0.000 abstract 2
- 230000003612 virological effect Effects 0.000 abstract 2
- 102000003810 Interleukin-18 Human genes 0.000 abstract 1
- 108090000171 Interleukin-18 Proteins 0.000 abstract 1
- 230000007423 decrease Effects 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 230000005745 host immune response Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18541—Use of virus, viral particle or viral elements as a vector
- C12N2760/18543—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
"PRODUçãO DE VìRUS SINCICIAL RESPIRATóRIO RECOMBINANTE EXPRESSANDO MOLéCULAS MODULADORAS IMUNES". São providos vírus sinciciais respiratórios (RSV) recombinantes, que expressam uma ou mais moléculas moduladoras imunes. O vírus recombinante é modificado por adição ou substituição de uma seq³ência de polinucleotídeos codificando a molécula moduladora imune, que é preferivelmente uma citocina. A introdução da citocina aumenta, diminui ou, de outro modo, intensifica os aspectos da biologia viral e/ou respostas imunes do hospedeiro ao RSV para facilitar o uso de vacina do vírus. As citocinas para uso dentro da invenção incluem, mas não são limitadas, à interleucina 2 (IL2), interleucina 4 (IL-4), interleucina 5 (IL-5), interleucina 6 (IL-6), ou interleucina 18 (IL-18), fator de necrose tumoral (TNF) alfa, interferon (IFN) gama, e fator estimulante de colónias de granulócitos-macrófagos (GM-CSF). O polinucleotídeo ou molécula moduladora imune é preferivelmente adicionado ou substituído no genoma viral recombinante, ou antigenoma, tipicamente em um local intergênico ou outro local não codificador; como um gene separado, mas podendo ser de outro modo expresso, por exemplo, como uma proteína de fusão.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14342599P | 1999-07-13 | 1999-07-13 | |
PCT/US2000/019042 WO2001004271A2 (en) | 1999-07-13 | 2000-07-12 | Respiratory syncytial viruses expressing immune modulatory molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0013202A true BR0013202A (pt) | 2002-09-24 |
Family
ID=22504018
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0013202-0A BR0013202A (pt) | 1999-07-13 | 2000-07-12 | Produção de vìrus sincicial respiratório recombinante expressando moléculas moduladoras imunes |
Country Status (11)
Country | Link |
---|---|
US (1) | US20050220767A1 (pt) |
EP (1) | EP1194581A2 (pt) |
JP (1) | JP2003512817A (pt) |
KR (1) | KR20020092889A (pt) |
CN (1) | CN1384883A (pt) |
AU (1) | AU783900B2 (pt) |
BR (1) | BR0013202A (pt) |
CA (1) | CA2379362A1 (pt) |
IL (1) | IL147436A0 (pt) |
MX (1) | MXPA02000490A (pt) |
WO (1) | WO2001004271A2 (pt) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7485440B2 (en) | 1995-09-27 | 2009-02-03 | The United States Of America As Represented By The Department Of Health And Human Services | Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2 |
US6699476B1 (en) | 1996-07-15 | 2004-03-02 | Peter L. Collins | Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules |
KR100894670B1 (ko) | 1996-07-15 | 2009-04-22 | 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 에즈 레프리젠티드 바이 더 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈 | 클론닝된 뉴클레오타이드 서열로부터 약독화된 호흡기 세포융합 바이러스 백신의 생산 |
US20030082209A1 (en) | 2000-07-05 | 2003-05-01 | Skiadopoulos Mario H. | Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines |
US7632508B2 (en) | 1997-05-23 | 2009-12-15 | The United States Of America | Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines |
US7201907B1 (en) | 1997-05-23 | 2007-04-10 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines |
US7951383B2 (en) | 1997-05-23 | 2011-05-31 | The United States Of America As Represented By The Department Of Health And Human Services | Attenuated parainfluenza virus (PIV) vaccines |
US7662397B2 (en) | 1997-07-15 | 2010-02-16 | The United States Of America As Represented By The Department Of Health And Human Services | Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes |
US20040005542A1 (en) | 2001-06-22 | 2004-01-08 | Krempl Christine D | Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes |
BR0013195A (pt) | 1999-07-09 | 2002-07-23 | Government Of The Us Dept Of H | Produção de vacinas de virus sincicial respiratório quimérico humano-bovino, atenuado |
AUPR381601A0 (en) * | 2001-03-19 | 2001-04-12 | Monash University | Method of treating respiratory conditions |
US20050048030A1 (en) * | 2001-09-28 | 2005-03-03 | Raymond Pickles | Paramyxoviruses as gene transfer vectors to lung cells |
US20050079153A1 (en) * | 2002-08-14 | 2005-04-14 | Pfizer Inc. | Methods for enhancing immune functions in neonatal mammals by administration of IL-18 |
AU2003270824B2 (en) * | 2002-09-18 | 2009-02-19 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Recovery of recombinant human parainfluenza virus type 2 (HPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens |
KR20060129013A (ko) * | 2004-01-13 | 2006-12-14 | 가부시키가이샤 디나벡크 겐큐쇼 | 면역자극성 사이토카인을 코드하는 마이너스 가닥 rna 바이러스 벡터를 사용하는 종양의 유전자 치료 |
US20100278864A1 (en) * | 2005-12-14 | 2010-11-04 | University Of Georgia Research Foundation, Inc. | Rabies Vaccine |
EP2313428A2 (en) * | 2008-07-01 | 2011-04-27 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Recombinant human parainfluenza type 1 viruses (hpiv1s) containing mutations in or deletion of the c protein are attenuated in african green monkeys and in ciliated human airway epithelial cells and are potential vaccine candidates for hpiv1 |
WO2015073507A1 (en) * | 2013-11-13 | 2015-05-21 | Cornell University | Stimulation of neonatal immunity |
EP3882851B1 (en) * | 2014-12-30 | 2023-01-18 | Ventana Medical Systems, Inc. | Method for co-expression analysis |
WO2017100756A1 (en) | 2015-12-11 | 2017-06-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant respiratory syncytial virus strains comprising ns1 and ns2 gene shifts |
CN105969741A (zh) * | 2016-06-15 | 2016-09-28 | 湖北省农业科学院畜牧兽医研究所 | 共表达h9亚型禽流感病毒ha和鸡白介素6蛋白的重组新城疫耐热疫苗株及制备方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4800078A (en) * | 1987-05-28 | 1989-01-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb |
US5716821A (en) * | 1994-09-30 | 1998-02-10 | Uab Research Foundation | Prevention and treatment of respiratory tract disease |
US20030054505A1 (en) * | 1997-09-26 | 2003-03-20 | Hong Jin | Recombinant rsv expression systems and vaccines |
WO1997012032A1 (en) * | 1995-09-27 | 1997-04-03 | The Government Of The United States Of America, As Represented By The Department Of Health And Human Services | Production of infectious respiratory syncytial virus from cloned nucleotide sequences |
US6923971B2 (en) * | 1995-09-27 | 2005-08-02 | The United States Of America As Represented By The Department Of Health & Human Services | Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes |
US6689367B1 (en) * | 1995-09-27 | 2004-02-10 | The United States Of America As Represented By The Department Of Health And Human Services | Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences |
KR100894670B1 (ko) * | 1996-07-15 | 2009-04-22 | 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 에즈 레프리젠티드 바이 더 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈 | 클론닝된 뉴클레오타이드 서열로부터 약독화된 호흡기 세포융합 바이러스 백신의 생산 |
BR0013195A (pt) * | 1999-07-09 | 2002-07-23 | Government Of The Us Dept Of H | Produção de vacinas de virus sincicial respiratório quimérico humano-bovino, atenuado |
-
2000
- 2000-07-12 WO PCT/US2000/019042 patent/WO2001004271A2/en not_active Application Discontinuation
- 2000-07-12 MX MXPA02000490A patent/MXPA02000490A/es not_active Application Discontinuation
- 2000-07-12 JP JP2001509475A patent/JP2003512817A/ja active Pending
- 2000-07-12 AU AU62112/00A patent/AU783900B2/en not_active Ceased
- 2000-07-12 EP EP00948641A patent/EP1194581A2/en not_active Withdrawn
- 2000-07-12 KR KR1020027000505A patent/KR20020092889A/ko not_active Application Discontinuation
- 2000-07-12 CA CA002379362A patent/CA2379362A1/en not_active Abandoned
- 2000-07-12 BR BR0013202-0A patent/BR0013202A/pt not_active Application Discontinuation
- 2000-07-12 IL IL14743600A patent/IL147436A0/xx unknown
- 2000-07-12 CN CN00810303A patent/CN1384883A/zh active Pending
-
2004
- 2004-08-11 US US10/917,984 patent/US20050220767A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MXPA02000490A (es) | 2004-09-27 |
CN1384883A (zh) | 2002-12-11 |
IL147436A0 (en) | 2002-08-14 |
KR20020092889A (ko) | 2002-12-12 |
JP2003512817A (ja) | 2003-04-08 |
WO2001004271A3 (en) | 2001-07-19 |
WO2001004271A2 (en) | 2001-01-18 |
AU783900B2 (en) | 2005-12-22 |
EP1194581A2 (en) | 2002-04-10 |
US20050220767A1 (en) | 2005-10-06 |
CA2379362A1 (en) | 2001-01-18 |
AU6211200A (en) | 2001-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0013202A (pt) | Produção de vìrus sincicial respiratório recombinante expressando moléculas moduladoras imunes | |
EP1637608B1 (en) | Recombinant adenoviral vector and methods of use | |
ES2260117T3 (es) | Terapia genica anticancerosa por modulacion de la respuesta inmunitaria y/o inflamatoria. | |
Dumoutier et al. | Viral and cellular interleukin-10 (IL-10)-related cytokines: from structures to functions | |
Rivas et al. | Dual role of p53 in innate antiviral immunity | |
Tsuruoka et al. | Inhibition of in vitro angiogenesis by lymphotoxin and interferon-γ | |
WO2018228538A1 (zh) | 重组单纯疱疹病毒及其制备方法和应用 | |
JPH06508039A (ja) | 抗腫瘍治療のためのサイトカインを発現する組換え型欠損アデノウイルス | |
RU2013106702A (ru) | Модифицированные дендритные клетки и их применение в лечении злокачественных опухолей | |
Ritter et al. | Stimulatory and inhibitory action of cytokines on the regulation of hCMV-IE promoter activity in human endothelial cells | |
Qian et al. | Therapy of cancer by cytokines mediated by gene therapy approach | |
Deng et al. | An oncolytic vaccinia virus armed with GM-CSF and IL-24 double genes for cancer targeted therapy | |
KR100788930B1 (ko) | 항암 조성물 | |
RU2006145306A (ru) | Аденовирусный/альфавитный гибридный вектор для эффективного введения и экспрессии терапевтических генов в опухолевые клетки | |
HUP9903921A2 (hu) | Tumor nekrózis faktorral rokon ligandum | |
Nakashima et al. | Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy | |
KR20080100640A (ko) | Il-12 및 il-23의 효율적인 공동발현 방법 | |
Essani et al. | Multiple anti-cytokine activities secreted from tanapox virus-infected cells | |
Lehmann et al. | Infection of macrophages by influenza A virus: characteristics of tumour necrosis factor-α (TNFα) gene expression | |
US20210395320A1 (en) | Protein heterodimer and use thereof | |
Brack et al. | Hematopoietic growth factors: interactions and regulation of production | |
Lei et al. | Induction of potent antitumor response by vaccination with tumor lysate-pulsed macrophages engineered to secrete macrophage colony-stimulating factor and interferon-γ | |
Yan et al. | Inhibition of lung adenocarcinoma transfected with interleukin 28A recombinant adenovirus (Ad-mIFN-λ2) in vivo | |
Lopes-Júnior et al. | Emerging cytokine networks in osteosarcoma | |
Hoang-Le et al. | A Kunjin replicon vector encoding granulocyte macrophage colony-stimulating factor for intra-tumoral gene therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 10 (VIII E IX), 11, 24 E 25 DA LPI. |
|
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |